Patheon news

Patheon, Inc. (Patheon) is a provider of commercial manufacturing and pharmaceutical development services (PDS) of prescription (Rx) and over-the-counter (OTC) drugs to the international pharmaceutical industry based at Mississauga,Canada

Patheon Inc. Announces Its Performance Guarantee

Patheon Inc. Announces Its Performance Guarantee

Patheon Inc. Extends Its Sterile Filling Capabilities to Include the Commercial Supply of Small Scale Specialty Products

Patheon Inc. Extends Its Sterile Filling Capabilities to Include the Commercial Supply of Small Scale Specialty Products

JLL Announces Extension of Its Offer to Acquire Patheon and Take Up of Deposited Restricted Voting Shares

JLL Announces Extension of Its Offer to Acquire Patheon and Take Up of Deposited Restricted Voting Shares

Patheon Inc. Recognized By Eli Lilly and Company As a Key Supplier

Patheon Inc. Recognized By Eli Lilly and Company As a Key Supplier

Patheon Inc. Names Interim Head of Pharmaceutical Development Services Unit and Chief Scientific Officer

Patheon Inc. Names Interim Head of Pharmaceutical Development Services Unit and Chief Scientific Officer

Patheon Commences Legal Action Against JLL and Responds to Dissident Requisition

Patheon Commences Legal Action Against JLL and Responds to Dissident Requisition

JLL Announces Extension of Its Offer To Acquire Patheon and Take Up of Deposited Restricted Voting Shares

JLL Announces Extension of Its Offer To Acquire Patheon and Take Up of Deposited Restricted Voting Shares

Patheon Special Committee Announces Court Rejection of JLL's Attempt to Limit its Mandate and Membership

Patheon Special Committee Announces Court Rejection of JLL's Attempt to Limit its Mandate and Membership

Patheon Announces Date of Second Quarter 2009 Financial Results Release, Conference Call and Webcast

Patheon Announces Date of Second Quarter 2009 Financial Results Release, Conference Call and Webcast

Patheon Special Committee Provides Update Following Shareholder Rejection of JLL's Inadequate Bid

Patheon Special Committee Provides Update Following Shareholder Rejection of JLL's Inadequate Bid

Syndicate content